An Innosuisse grant for a game-changing diabetes treatment
Type 1 diabetes is a disease in which the immune system destroys the beta cells of the pancreas, responsible for insulin production. Currently, the only treatment available consists of daily injections of artificial insulin, which are far from optimal and cannot avoid the risks of hypoglycemia.
Researchers from Prof. Roberto Coppari’s laboratory have recently discovered that a hormone, called S100A9, is capable of improving blood sugar control, while avoiding the most harmful side effects of insulin. The Diatheris spin-off, created by Roberto Coppari and one of his scientific collaborators Giorgio Ramadori, has received significant support from Innosuisse to advance the clinical development of this revolutionary therapy based on the S100A9 protein and to accelerate its industrial valorization.
Roberto Coppari (left) and Giorgio Ramadori (right), founders of the spin-off Diatheris. © UNIGE
19 Dec 2022